Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that
is reimagining therapeutic delivery, presented data on oral
delivery of a GLP-1 receptor agonist with its BioJet systemic oral
delivery platform in a short oral discussion titled “Evaluation of
the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist
Delivered through the BioJet™ Biotherapeutic Delivery Platform in
Swine” at the 59th annual meeting of the European Association for
the Study of Diabetes, in Hamburg, Germany.
“In recent studies, we assessed the bioavailability of
semaglutide when delivered via our autonomous next-generation
BioJet device in a porcine model. Across three studies, 96% of
animals (22/23) showed semaglutide in systemic circulation at
clinically relevant levels for up to ten days following
administration,” said Sharat Singh, PhD, Head of Research at Biora
Therapeutics. “Among the 22 animals dosed with semaglutide, oral
bioavailability averaged 20.5% ± 15.3%, compared to IV control,
which exceeds both the device performance and bioavailability
targets set by us and our collaborators,” continued Dr. Singh.
“The category-leading bioavailability results for our
autonomous, next-gen BioJet device, along with its ability to
deliver existing liquid formulations at multi-milligram doses
similar to injection, have enabled us to accelerate testing with
our collaborators’ molecules,” said Adi Mohanty, Chief Executive
Officer of Biora Therapeutics. “We are seeing increased interest in
our platform and continue to advance our stated goal to progress
our collaborations and rapidly work towards meaningful
partnerships,” continued Mr. Mohanty.
The studies included single, approximately 1 mg doses of
semaglutide in a liquid formulation delivered via the BioJet
device. Devices were administered endoscopically, as is typical in
a porcine model, and then released for autonomous activation. Blood
sampling was performed from zero to 240 hours post-dose, with
comparison to a control animal with drug administered
intravenously. The presentation can be viewed on the European
Association for the Study of Diabetes website and is also available
on the Biora Therapeutics website.
About the BioJet™ Systemic Oral Delivery
Platform Biora's BioJet systemic oral therapeutics
platform uses an ingestible capsule for needle-free, oral delivery
of large molecules designed to achieve systemic bioavailability and
replace injection for better management of chronic
diseases.
The BioJet platform uses an ingestible device designed to
transit through the digestive system and activate in the small
intestine, where liquid jets deliver drug directly into the small
intestine for uptake into systemic circulation. The BioJet device
is approximately the size of a multivitamin and is designed to
autonomously deliver a wide range of large molecules, such as
proteins, peptides, and nucleic acids, in liquid formulation at
multi-milligram doses, without requiring complex
reformulation.
Biora holds a comprehensive patent position for the BioJet
systemic oral delivery platform, with approximately 11 issued
patents and 27 pending applications that cover its delivery
platform and methods for using the platform to treat a disease or
condition in a patient using liquid jet delivery of a wide range of
drugs.
About Biora TherapeuticsBiora Therapeutics is
the biotech company that is reimagining therapeutic delivery. By
creating innovative smart pills designed for targeted drug delivery
to the GI tract, and systemic, needle-free delivery of
biotherapeutics, the company is developing therapies to improve
patients’ lives.
Biora is focused on development of two therapeutics platforms:
the NaviCap™ targeted oral delivery platform, which is designed to
improve outcomes for patients with inflammatory bowel disease
through treatment at the site of disease in the gastrointestinal
tract, and the BioJet™ systemic oral delivery platform, which is
designed to replace injection for better management of chronic
diseases through needle-free, oral delivery of large molecules.
For more information, visit bioratherapeutics.com or follow the
company on LinkedIn or Twitter.
Safe Harbor Statement or Forward-Looking
StatementsThis press release contains “forward-looking
statements” within the meaning of the “safe harbor” provisions of
the Private Securities Litigation Reform Act of 1995, which
statements are subject to substantial risks and uncertainties and
are based on estimates and assumptions. All statements, other than
statements of historical facts included in this press release,
including statements concerning the progress and future
expectations and goals of our research and development and clinical
efforts, are forward-looking statements. In some cases, you can
identify forward-looking statements by terms such as “may,”
“might,” “will,” “objective,” “intend,” “should,” “could,” “can,”
“would,” “expect,” “believe,” “design,” “estimate,” “predict,”
“potential,” “plan,” “target,” or the negative of these terms, and
similar expressions intended to identify forward-looking
statements. These statements reflect our plans, estimates, and
expectations, as of the date of this press release. These
statements involve known and unknown risks, uncertainties and other
factors that could cause our actual results to differ materially
from the forward-looking statements expressed or implied in this
press release. Such risks, uncertainties, and other factors
include, among others, our ability to innovate in the field of
therapeutics, our ability to make future filings and initiate
clinical trials on expected timelines or at all, our ability to
obtain and maintain regulatory approval or clearance of our
products on expected timelines or at all, our plans to research,
develop, and commercialize new products, the unpredictable
relationship between preclinical study results and clinical study
results, our expectations regarding allowed patents or intended
grants to result in issued or granted patents, our expectations
regarding opportunities with current or future pharmaceutical
collaborators, our ability to raise sufficient capital to achieve
our business objectives, and those risks described in “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations” in our Annual Report on Form
10-K for the year ended December 31, 2022 filed with the SEC and
other subsequent documents, including Quarterly Reports, that we
file with the SEC.
Biora Therapeutics expressly disclaims any obligation to update
any forward-looking statements whether as a result of new
information, future events or otherwise, except as required by
law.
Investor ContactChuck PadalaManaging Director,
LifeSci AdvisorsIR@bioratherapeutics.com(646) 627-8390
Media Contactmedia@bioratherapeutics.com
Biora Therapeutics (NASDAQ:BIOR)
과거 데이터 주식 차트
부터 5월(5) 2024 으로 6월(6) 2024
Biora Therapeutics (NASDAQ:BIOR)
과거 데이터 주식 차트
부터 6월(6) 2023 으로 6월(6) 2024